DexcomDXCMEarnings & Financial Report
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
DXCM Q1 2026 Key Financial Metrics
売上高
$1.3B
粗利益
$792.7M
営業利益
$323.0M
純利益
$267.3M
粗利益率
62.9%
営業利益率
25.6%
純利益率
21.2%
前年比成長
21.6%
EPS
$0.67
資金フロー
Dexcom Q1 2026 Financial Summary
Dexcom reported revenue of $1.3B for Q1 2026, with a net profit of $267.3M (21.2% margin). Cost of goods sold was $466.9M, operating expenses totaled $469.7M.
Key Financial Metrics
| Total Revenue | $1.3B |
|---|---|
| Net Profit | $267.3M |
| Gross Margin | 62.9% |
| Operating Margin | 25.6% |
| Report Period | Q1 2026 |
Dexcom Annual Revenue by Year
Dexcom annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.7B |
| 2024 | $4.0B |
| 2023 | $3.6B |
| 2022 | $2.9B |
損益計算書
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $1.00B | $994.2M | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.26B |
| 前年比成長 | 15.3% | 2.0% | 7.6% | 12.5% | 15.2% | 21.6% | 13.1% | 21.6% |
貸借対照表
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $6.80B | $6.35B | $6.48B | $6.75B | $7.33B | $7.50B | $6.34B | $6.34B |
| 総負債 | $4.36B | $4.37B | $4.38B | $4.49B | $4.75B | $4.77B | $3.59B | $3.59B |
| 株主資本 | $2.43B | $1.98B | $2.10B | $2.27B | $2.57B | $2.73B | $2.75B | $2.75B |
キャッシュフロー
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| 営業CF | $279.4M | $199.5M | $301.4M | $183.8M | $303.0M | $659.9M | $294.0M |
Other Health Care Companies
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
BAX
Baxter International
売上高
$3.0B
純利益
$-1.1B
BDX
Becton Dickinson
売上高
$5.3B
純利益
$382.0M
BSX
Boston Scientific
売上高
$5.3B
純利益
$670.0M
EW
Edwards Lifesciences
売上高
$1.6B
純利益
$291.1M
GEHC
GE HealthCare
売上高
$5.7B
純利益
$588.0M
HOLX
Hologic
売上高
$1.0B
純利益
$179.1M
IDXX
Idexx Laboratories
売上高
$1.1B
純利益
$274.6M
PODD
Insulet Corporation
売上高
$783.7M
純利益
$101.6M
ISRG
Intuitive Surgical
売上高
$2.9B
純利益
$794.8M